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ABSTRACT
The roles of virus-derived small RNAs (vsRNAs) have
been studied in plants and insects. However, the gen-
eration and function of small RNAs from cytoplas-
mic RNA viruses in mammalian cells remain unex-
plored. This study describes four vsRNAs that were
detected in enterovirus 71-infected cells using next-
generation sequencing and northern blots. Viral in-
fection produced substantial levels (>105 copy num-
bers per cell) of vsRNA1, one of the four vsRNAs. We
also demonstrated that Dicer is involved in vsRNA1
generation in infected cells. vsRNA1 overexpression
inhibited viral translation and internal ribosomal en-
try site (IRES) activity in infected cells. Conversely,
blocking vsRNA1 enhanced viral yield and viral pro-
tein synthesis. We also present evidence that vs-
RNA1 targets stem-loop II of the viral 5′ untranslated
region and inhibits the activity of the IRES through
this sequence-specific targeting. Our study demon-
strates the ability of a cytoplasmic RNA virus to gen-
erate functional vsRNA in mammalian cells. In addi-
tion, we also demonstrate a potential novel mecha-
nism for a positive-stranded RNA virus to regulate
viral translation: generating a vsRNA that targets the
IRES.
INTRODUCTION
Cells produce small RNAs, which are noncodingRNAs 20–
30 nucleotides (nt) in length (1). These small RNAs can fine-
tune the biological functions of cells by modulating gene
expression and modifying the genome (2,3). For example,
endogenous microRNAs (miRNAs) regulate specific gene
expression and control the associated downstream activities
(2). Another type of cellular small RNAs, PIWI-interacting
RNAs (piRNAs), maintain genomic integrity by preventing
the invasion of transposable elements (3).
Mammalian cells produce numerous small RNAs via a
canonical miRNA biogenesis pathway that involves nuclear
processing by an RNase III-type protein, Drosha, and sub-
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sequent cytoplasmic processing by another RNase III-type
protein, Dicer (1). Viruses that replicate in the nucleus, such
as deoxyribonucleic acid (DNA) viruses and retroviruses,
can produce their own small RNAs through the canoni-
cal miRNA biogenesis pathway. These virus-derived small
RNAs (vsRNAs) either fine-tune viral replication or inhibit
antiviral mechanisms in infected cells (4–6). Alternatively,
Dicer enzymes in plant and insect cells process the genome
of a cytoplasmic RNA virus into small RNAs. Infected cells
use these vsRNAs as an antiviral defence mechanism to re-
duce viral replication through RNA interference (7). Con-
versely, West Nile virus uses Dicer in mosquito cells to pro-
duce miRNA-like vsRNAs for the benefit of the virus (8).
However, similar mechanisms for generating vsRNA and
RNA-based defences against cytoplasmic RNA viruses in
mammals require further research (2,9–10).
Recent studies have shown that cytoplasmic RNA viruses
can induce non-canonical cytoplasmic miRNA biogenesis
pathways in mammalian cells (11,12). For example, an en-
gineered Sindbis virus with a primary miRNA hairpin in
its subgenomic RNA generated functional miRNA through
a Dicer-dependent, DGCR8-independent pathway (12,13).
These studies have suggested that a cytoplasmic RNA virus
containing a primary miRNA-like hairpin may be capable
of producing vsRNA through its own structuredRNA in in-
fected mammalian cells. In addition, deep sequencing tech-
niques have been used to identify vsRNAs and siRNAs in
mammalian cells infected with cytoplasmic RNA viruses
(14–16). However, the functions of these vsRNAs are still
debated (17).
Similar to poliovirus, enterovirus 71 (EV71) is a positive-
stranded RNA virus that replicates in the cytoplasm. EV71
outbreaks have occurred worldwide, and EV71 infection is
associated with severe neurological diseases and high mor-
tality rates (18,19). The 5′ untranslated region (5′UTR) of
the EV71 genomic RNA is highly structured (20,21); it con-
tains a cloverleaf structure that is essential for viral RNA
replication and an internal ribosomal entry site (IRES) that
is responsible for viral translation (22,23). Because positive-
stranded viruses use the sameRNA template for both trans-
lation and replication, viruses must regulate their transla-
tion (or IRES activity) (24,25). Recently discovered proteins
called IRES trans-acting factors (ITAFs) can regulate EV71
IRES activity (19,26–28).
In this study, we showed that a cytoplasmic positive-
strandedRNAvirus generated functional vsRNAs inmam-
malian cells. One vsRNA (vsRNA1) down-regulated viral
translation by targeting the stem-loop II region of the vi-
ral IRES. This study demonstrated a novel mechanism by
which virus self-regulates its translation by generating a
RNA-based ITAF.
MATERIALS AND METHODS
Deep sequencing and data analysis
SF268 (human glioblastoma) cells were mock-infected or
virus-infected with Enterovirus 71 strain Tainan/4643/98
(GenBank accession number: AF304458.1) at a moi of 40.
After 6 h post-infection (p.i.), the total RNA was extracted
with a TRIzol reagent (Invitrogen) according to manufac-
turer instructions. The integrity and quality of the total
RNA was evaluated using an Agilent 2100 BioAnalyzer
(Agilent Technologies). Forty micrograms of RNA were
sent to the Beijing Genomics Institute (BGI) for Solexa
analysis. Small RNAs under 50 bases were PAGE-purified
and ligated with a pair of Solexa adaptors to their 5′ and
3′ ends. The small RNAs were then reverse transcribed and
amplified by PCR using a pair of adaptor primers. The re-
sulting cDNA library then underwent cluster generation
and sequencing analysis using the Illumina HiSeq 2000 se-
quencing system (Illumina). Raw sequencing data were an-
alyzed using a CLC Genomics Workbench 4.7 (CLC Bio).
Raw reads were filtered by discarding low-quality reads and
removing adaptor sequences to generate clean and usable
reads with sizes ≥15 nt and ≤50 nt. To discard unique se-
quences originating from cellular miRNA and other non-
coding RNA, including rRNA, tRNA, small nuclear RNA
(snRNA) and small nucleolar RNA (snoRNA), clean reads
were first mapped to themiRBase version 18 (www.mirbase.
org) and Homo sapiens.GRCh37.65.ncrna (www.ensembl.
org). The remaining reads were then mapped to the EV71
genome (strain 4643), and only the reads that matched the
EV71 genome perfectly were selected for further analysis.
The mapping results were exported from CLC Genomics
Workbench and were illustrated by Prism 5 (GraphPad).
vsRNA detection in EV71-infected cells
SF268 and RD cells were mock-infected or infected with
EV71/4642/MP4 at an MOI of 40. At 6 h p.i., small
RNA fractions with sizes ≤ 200 nt were isolated and en-
riched using the mirVana miRNA Isolation Kit (Ambion).
Ten microgram samples of small RNA were separated on
15% polyacrylamide/8M urea denaturing gel, electroblot-
ted to GeneScreen Plus nylon membranes (PerkinElmer),
and UV cross-linked for fixation. The oligonucleotides use
d to probe each vsRNA were 5′-TGATCGTTGATTTAC
AGCTTCTAAGTTAC-3′ for vsRNA1, 5′-TGATACTCA
GTCCGGGGAAAC-3′ for vsRNA2, 5′-GTCGGTTCC
GCTGCAGAGTTGCCCG-3′ for vsRNA3, 5′-TGAGA
GTGATCACAGACTTCAG-3′ for vsRNA4 and 5′-AAA
CAGAAGTGCTTGATCA-3′ for 163--181 fragment. The
oligonucleotide probes were generated by 5′-end-labelled
with [-32P]ATP using T4 polynucleotide kinase (Promega).
Prehybridization and hybridization of the membrane were
conducted with an ULTRAhyb Hybridization Buffer (Am-
bion) containing denatured salmon sperm DNA at 42◦C.
After probe hybridization, the probed membranes were
washed twice with 2× SSC, and 0.1% SDS at 42◦C for 15
min, and were then processed by autoradiography.
Co-immunoprecipitation of Ago2 and miRNA-21 in infected
cells
RNAs in cell lysates from EV71-infected SF268 cells were
immunoprecipitated with anti-Ago2 antibody (ab32381,
Abcam) at 4◦C for 4 h. The co-precipitated RNAs were pu-
rified from the lysates after treated with DNase and Pro-
tease K. vsRNA1 and miR-21 in the co-precipitation were
detected by northern-blotting using 5′32P-radiolabelled pr
obes (5′-TGATCGTTGATTTACAGCTTCTAAGTTAC
-3′ for vsRNA1 and 5′-TCAACATCAGTCTGATAAGCT
A-3′ for miR-21).
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Plasmids and Constructs
Plasmids pT7-EV71-IRES and pGL3-EV71-5 -UTR-
Fluc were constructed previously (28,29). The pGL3-
EV71-5′ UTR-Fluc was adopted as the template for
constructing mutant EV71-5′ UTR plasmids by using
site-direct mutagenesis kit (Stratagene) and primers
5′-(TGTGGCACACCAGTCATACCTACTTCAAGC
ACTTCTGTTTCCCCG)-3′ and 5′-(CGGGGAAACA
GAAGTGCTTGAAGTAGGTATGACTGGTGTGCC
ACA)-3 for mut 163–165, 5′-(AGTCATACCTTGAT
CAAGCACAAGTGTTTCCCCGGACTGAGTATC)
-3′ and 5′-(GATACTCAGTCCGGGGAAACACTTGT
GCTTGATCAAGGTATGACT)-3′ for mut 174–176,
5′-(TGTGGCACACCAGTCATACCTACTTCAAGC
ACAAGTGTTTCCCCGGACTGAGTATC)-3′ and 5′
-(GATACTCAGTCCGGGGAAACACTTGTGCTT
GAAGTAGGTATGACTGGTGTGCCACA)-3′ for mut
163–165+174–176, 5′-(GGCGACCATGGCAGTGGCTG
CCAAGGCGGCCTGCCCATGGAGAAA)-3′ and 5′
-(TTTCTCCATGGGCAGGCCGCCTTGGCAGCCAC
TGCCATGGTCGCC)-3′ for mut 367–369, 5′-(ATGG
TGACAATCAAAAAGTTGAATCCATATAGCTATTG
GATTGGCC)-3′ and 5′-(GGCCAATCCAATAGCTAT
ATGGATTCAACTTTTTGATTGTCACCAT)-3′
for mut 617–619. The plasmid pGL3-Polio-5′-UTR-Flu
was constructed as follows: the 5′ UTR of poliovirus was
amplified by PCR using the poliovirus replicon (30) primer
5′-(CCGCTCGAGTAATACGACTCACTATAGGGA
GATTAAAACAGCTCTGGGGTTG)-3′, which contai
ns the T7 promoter sequence and primer 5′-(AATCAG
ACAATTGTATCATAATGGAAGACGCCAAAAAC
AT)-3′. The polio-5′ UTR combined with the firefly luci
ferase gene was subsequently amplified by primers 5′-(CC
GCTCGAGTAATACGACTCACTATAGGGAGATT
AAAACAGCTCTGGGGTTG)-3′ and 5′-(ATGTTTTT
GGCGTCTTCCATTATGATACAATTGTCTGATT)-3′.
The segment containing polio-5′ UTR and the firefly
luciferase gene was then cloned into vector pGL3 by XhoI
and MluI. Plasmid FLAG-Dicer, FLAG-Dicer-MUT
and FLAG-Dicer-dsRBD were constructed as follows:
the WT and mutant (MUT) human Dicer cDNA were
generated using PCR from the plasmids containing Dicer
cDNA (WT or with quadruple mutants on 44th and
110th amino acids in Dicer RNaseIII Domain a and
Domain b) in a pDEST8 vector [pDEST8-Dicer-6His and
pDEST8-Dicer 44AB/110AB) were gifts from Dr. Witold
Filipowicz (31)] using 5′-(ACGACAAGCTTATGAA
AAGCCCTGCTTTG)-3′ primer containing the HindIII
site and 5′-(AGTCCAAGGGTTATCGATTCCATGGC
TATA)-3′ primer containing a stop codon and a KpnI
site. Truncated Dicer cDNA with dsRBD domain deletion
(dsRBD), which lacks the 57 C-terminal amino acids,
was generated from plasmid Dicer-pDEST8 by PCR using
5′-(CCTTGGTCTTTGACGGATTCCATGGCTATA)-3′
as the downstream primer. The generated cDNAs were
digested by HindIII and KpnI and inserted into the vec-
tor p3XFLAG-Myc-CMV-25 (Sigma-Aldrich) to form
the FLAG-Dicer, FLAG-Dicer-MUT and FLAF-Dicer-
dsRBD plasmids. The plasmid for the EV71 replicon was
generated as follows: the DNA fragment containing the
T7 promoter, EV71-5′ UTR, and firefly luciferase (FLuc)
gene was sub-cloned from pGL3-EV71-5′-UTR-Fluc into
vector yT&A (Yeastern Biotech). The DNA fragment
containing the EV71 P2-P3 polyprotein region was am-
plified from the EV71 infectious clone (32) and cloned
into downstream of the FLuc gene in yT&A-EV71-5′
UTR-FLuc. To generate the vsRNA1 deletion mutant on
the replicon plasmid, a set of primers, 5′-(TTCGGGGG
AAGGGGAGTAAA)-3′ and 5′-(TAGCAGGTGTGGCA
CACCAG)-3′ were used for amplifying the DNA fragment
from the EV71 replicon plasmid. The amplified DNA
was treated with DpnI (New England BioLabs), and then
treated with T4 DNA ligase (New England BioLabs).
The EV71 Replicon plasmid containing the vsRNA1
deletion mutation was selected and confirmed through
sequencing. Plasmid for shDicer was generated by an-
nealing synthetic shDicer oligonucleotides (33) into the
pSilencer 2.1-U6 hygro vector. The plasmid for shAgo2
was a gift from Dr. Shobha Vasudevan (34). To construct
sponge-vsRNA1 plasmids, a DNA fragment contains
10 repeats of the sequence complement of vsRNA1 (5′-
TGATCGTTGATTTACAGCTTCTAAGTTAC-3′) was
cloned into pcDNA3.1(+) vector (Invitrogen) by HandIII
and EcoRI. To construct sponge-controlled plasmids, a
DNA fragment contain 10 repeats of sequence scrambled
(5′-TCCGTGCCAAGTTACTAGAAAAGTTCAAT-
3′) was cloned into pcDNA3.1(+) in the BamHI and
XhoI restriction sites. The plasmid pT7-EV71-3′UTR
was generated as fellows: The cDNA of EV71 3′UTR
was amplified by PCR using a set of primers, 5′-(AACT
TAAGCTTTAAATTTACAGTTTGTAACT)-3′ and 5′-
(TGCAGAATTCGCTATTCTGGTTATAACAAA)-3′.
The amplified DNA containing 3′UTR sequence was
cloned into vector pcDNA3.1(+) by restriction enzyme
sites, HindIII and EcoRI.
Western blot analysis
Polyvinylidene difluoride (PVDF)membranes were blocked
with Tris-buffered saline/0.1% (vol/vol) Tween 20 contain-
ing 5% non-fat dry milk and probed with the indicated an-
tibodies. Antibodies against Dicer (sc-136981; Santa Cruz),
Drosha (ab12286, Abcam), La protein (sc-33593, Santa
Cruz), PTB (sc-16547, Santa Cruz), HuR (39–0600, Invit-
rogen), KSRP / FBP2 (A302–021A, Bethyl laboratories),
hnRNPA1 (GTX106208, GenTex), FLAG (SIGMA) and
actin (Chemicon) were used. After washing, the membranes
were incubated with an HRP-conjugated anti-mouse anti-
body or HRP-conjugated anti-rabbit antibody, as appropri-
ate (diluted 1:5000). HRP was detected using the Western
Lightning Chemiluminescence Kit, following the manufac-
turer instructions (GE Healthcare).
Immunoprecipitation of FLAG-Dicer proteins
The SF268 cells grown in each well of a 6-well plate were
transfected with 5 g of plasmids FLAG-Dicer, FLAG-
Dicer-MUT, or FLAG-Dicer-dsRBD by 5 l of Lipofec-
tamine 2000 (Invitrogen). After 48 h post-transfection, the
transfected cells were lysed by incubation with a lysis buffer
(500 mM NaCl, 20 mM Tris-Cl, pH 8.0, 1 mM EDTA, 1%
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Triton X-100) on ice for 30 min and then subjected to a
vortex for 30 s at room temperature. The cell lysates were
harvested from the supernatant of the lysed cells after cen-
trifugation at 16,000 g for 10 min. Two milligrams of cell
lysates from the transfected cells were incubated with 40
l of the resin conjugated with anti-FLAG M2 antibody
(Sigma) at 4◦C for 2 h. The immunoprecipitated FLAG-
Dicer proteins with resin were washed in a lysis buffer four
times and then washed with Buffer D (200mMKCl, 20mM
Tris-Cl pH 8.0, 20 mM EDTA) three times. The resin with
FLAG-Dicer proteins was then resuspended in 60l of a re-
suspension buffer (40 mMTris-Cl pH 7.5, 500 mMNaCl, 5
mMMgCl2, 40% glycerol) and stored in a freezer at –80◦C.
In vitro transcription
To generate EV71-IRES-FLuc reporter RNA and Polio-
IRES-FLuc reporter RNA, plasmid pGL3-EV71-5′-UTR-
Fluc and pGL3-Polio-5′-UTR-Flu were linearized by
XhoI to be used as the template for in vitro transcrip-
tion. To generate cap-RLuc reporter RNA, the DNA
fragment containing the T7 promoter and Renilla gene
were amplified from the pRH plasmids (26) by us-
ing primers [5′-(TAATACGACTCACTATAGGCTAGC
CACCATGACTTCGAAAGTTTATGATC)-3′] and [5′-
(TTATTGTTCATTTTTGAGAACT)-3′] as the template
for in vitro transcription. The cap structure on the 5′-
end of the Renilla reporter RNA was added by the Vac-
cinia Capping System (New England BioLabs). To gen-
erate EV71 5′ UTR RNA, a T7 promoter-EV71-5′ UTR
fragment flanked by EcoRI site was excised from the plas-
mid pT7-EV71-IRES to form a template for in vitro tran-
scription. To generate EV71 3′UTR RNA, a T7 promoter-
EV71–3′UTR fragment flanked by EcoRI site was excised
from the plasmid pT7-EV71–3′UTR to form a template for
in vitro transcription. To generate EV71 replicon RNA, the
EV71 replicon plasmid was linearized by SalI for produc-
ing the DNA template for in vitro transcription. RNA tran-
scripts were synthesized using a MEGAscript T7 kit (Am-
bion), following the manufacturer instructions. To generate
sponge RNA against vsRNA1 or control-sponge RNA, the
sponge-vsRNA1 plasmid/sponge-control plasmid was lin-
earized by EcoRI/XhoI. The linearized DNA was used as
template for in vitro transcription.
Biotinylated EV71 5′ UTR RNA was synthesized in a 20
l MEGAscript transcription reaction mixture by adding
1.25 l of 20 M of Bio-16-UTP, a biotinylated UTP that
can replace UTP in the in vitro transcription for RNA la-
belling (Roche). The 32P-labelled EV71 5′ UTR RNA was
synthesized in a 20 l MEGAscript transcription reaction
mixture by adding -32P-UTP. Synthesized RNAs were pu-
rified using the RNeasy Protect Mini Kit (Qiagen).
IRES-FLuc and Cap-RLuc reporter assay
To assay the effects of vsRNA1 on EV71 IRES or Po-
liovirus IRES activities, SF268 cells were cotransfected
with either 160 pmol of vsRNA1 mimic (5′-GUAACUUA
GAAGCUGUAAAUCAACGAUCA-3′) or scrambled vs-
RNA1 (5′-AAUGCUAUGAGACUAAUGAUACCAAG
ACU-3′) concurrently with EV71 IRES FLuc or Polio
IRES FLuc or cap-RLuc reporter RNAs. After 6 h of
reporter RNA transfection, cell extracts from the trans-
fected cells were prepared in Cell Culture Lysis Reagent
(Promega). The firefly luciferase activity of the cell extracts
was assayed using the Luciferase assay system (Promega),
following the manufacturer instructions. The renilla lu-
ciferase activity of the cell extracts was assayed using the
Dual luciferase reporter assay system (Promega).
Detection of IFN- mRNA in RNAs-treated cells
RNA from 106 of SF268 cells treated with 2 g of Lipo-
fectamine 2000, transfected with 320 pmol of vsRNA1 or
scrambled vsRNA1 or 2 g of poly (I:C) (Sigma) for 24
h were isolated using TRIzol reagent (Sigma). Two g of
the RNA from each sample was taken as template to gen-
erate complementary DNA (cDNA) by reverse transcrip-
tion using oligo(dT) primer. To detect the IFN- cDNA
by RT-PCR, a set of primers, forward 5′-(AGAAGGAG
GACGCCGCATTG)-3′ and reverse 5′-(TCAGTTTCGG
AGGTAACCTG)-3′ were used. The cDNA of -actin was
amplified using primers 5′-(CTACAATGAGCTGCGTGT
GG)-3′ and 5′-(GCTCATTGCCAATGGTGATG)- 3′. The
amplified DNA was then submitted to agarose gel elec-
trophoresis. The detection of IFN- mRNA by real-time
quantitative PCR was performed as previously described
(35). The results were normalized to the levels of the house-
keeping gene -actin using the 2-CT method.
In vitro Dicer cleavage assay of EV71 5′UTR and replicon
RNA
To assay recombinant Dicer cleaving EV71 5′ UTR RNA,
10,000 cpm of 32P-labelled EV71 5′ UTR RNA was incu-
bated with various amounts (from 0.05 to 0. 25 U) of com-
mercial recombinant Dicer enzyme (T510002, Genlantis)
and cleavage buffer (20 mM Tris-Cl pH 7.5, 250 mMNaCl,
2.5 mMMgCl2 and 0.1 g/l bacteria tRNA) at an overall
volume of 10 l. The mixture was incubated at 37◦C for 1.5
h. After incubation, the reactants were mixed with 10 ml
of loading dye (80% formamide, 1 mM EDTA, 0.1% bro-
mophenol blue and 0.1%Xylene Cyanol) and assayed using
denaturing 3.5% polyacrylamide gel (1X TBE, 8M Urea,
acrylamide [19:1; acrylamide:bisacrylamide]). For gener-
ating svRNA by Dicer-treated EV71 5′ UTR, 10 g of
EV71 5′ UTR RNA was treated with 1 U of a recom-
binant dicer enzyme (T510002, Genlantis), following the
manufacturer instructions. The Dicer-treated RNAs were
assayed by northern blotting. To determine the catalytic
activity of FLAG-Dicer proteins, each reaction involved
10 l of immunoprecipitated FLAG-Dicer proteins with
resin. Next, 400,000 cpm samples of 32P EV71 5′ UTR
RNAs were incubated with an immunoprecipitated FLAG-
Dicer, FLAG-Dicer-MUT, or FLAG-Dicer-dsRBD pro-
teins, cleavage buffer and an additional 4 U/l of RNase-
OUT recombinant ribonuclease inhibitor (Invitrogen) in a
volume of 10 l. The mixtures were incubated at 37◦C for
1.5 h. After incubation, the treated RNAs were isolated
from the reactants by the TRIzol protocol (Invitrogen) and
assayed by denaturing 3.5% polyacrylamide gel (1X TBE,
8M Urea, acrylamide [19:1; acrylamide:bisacrylamide]).
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Pull-down assay for biotinylated EV71 5′UTR RNA with
streptavidin beads
Three micrograms of biotinylated EV71 5′ UTR RNA and
200 g of cell extracts from SF268 (prepared as described
previously (28)]) were added to the RNA interaction buffer
(30mMTris-HCl pH 6.8, 3mMMgCl2, 50mMNaCl, 0.1%
Triton X-100, 20% glycerol, 1 mMDTT and 2 mM EDTA)
in a reaction volume of 100l. The reactionmixture was in-
cubated at 30◦C for 15 min. The StreptavidinMagneSphere
Paramagnetic Particles (Promega) were washed with a 0.5×
SSC buffer (150 mMNaCl and 15 mM trisodium citrate di-
hydrate) three times and were then added to the reaction
mixture for 10 min at room temperature. For the compe-
tition assay, a poly(A) RNA was used (Sigma). The pull-
down protein-RNA complex was washed in 0.1× SSC five
times. After washing, the beads with the pull-down protein-
RNA complex were incubated with an SDS–PAGE sample
buffer at 25◦C for 10 min and then centrifuged at 21,000 g
for 10 min. The supernatant containing the pull-down pro-
teins was then assayed by western blotting.
Native gel analysis of the Dicer-EV71 5′UTR complex
Recombinant Dicer Enzyme (T510002, Genlantis) was in-
cubated in 20 mM Tris-HCl pH 7.5, 50 mM KCl, 5 mM
MgCl2, 1 mM DTT, and 5% RNaseOUT for 10 min at
room temperature at a volume of 10 l, after which 18,000
cpm of 32P-labelled EV71 5′ UTR RNA was added to
the Dicer reaction for an overall volume of 15 l, and
was cooled on ice for 30 min. To study the competition
by cold EV71 5′UTR RNA, unlabelled EV71 5′ UTR
RNA and 32P-labelled EV71 5′ UTR RNA were added
to the reaction simultaneously. After incubation, a 1.5
l loading buffer (60% glycerol, 0.2% bromophenol blue)
was added to the reaction. The RNA-protein complex
was assayed by non-denaturing 3% polyacrylamide TBE
gels (29:1; acrylamide:bisacrylamide) and was detected by
autoradiography.
Fluorescence microscopy
RD cells grown on glass cover slips were infected with
EV71/4643/MP4 at a MOI of 40. At 6 h p.i., the infected
cells were washed 3x with phosphate buffered saline (PBS).
The cells on the cover slips were fixed with 4% (wt/vol)
paraformaldehyde at room temperature for 20 min. After
washing 3x with PBS, the cells on the cover slips were per-
meabilized in 0.3% Triton X-100 at room temperature for
5 min and washed again with PBS. For Dicer and viral
2B immunostaining, the samples were blocked in solution
[PBS, containing 5% bovine serum albumin (BSA)] for 60
min at 37◦C and then incubated with an anti-Dicer anti-
body (sc-136981, Santa Cruz) and polyclonal anti-2B anti-
body (1:200) for 2 h at 37◦C. After washing with PBS for
three times, the samples were reacted with Alexa Fluor 488-
conjugated goat anti-mouse IgG (Life technologies) and
Alexa Fluor 568-conjugated goat anti-rat IgG (Life tech-
nologies) at 37◦C for 1.5 h. For Drosha and viral 3D im-
munostaining, the samples were blocked in solution (PBS,
containing 5% bovine serum albumin (BSA)) for 60 min
at 37◦C and then incubated with an anti-Drosha antibody
(1:25) (ab12286, Abcam) andmonoclonal anti-3D antibody
(1:200) for 2 h at 37◦C. After washing 3x with PBS, the sam-
ples were incubated with Alexa Fluor 488-conjugated goat
anti-rabbit IgG and Alexa Fluor 594-conjugated goat anti-
mouse IgG (Life technologies) at 37◦C for 1.5 h.After wash-
ing with PBS, the samples were treated with Hoechst 33258
for 15 min at room temperature and washed with PBS three
more times. Finally, the cover slips with adhering cells were
placed on a glass slide and sealed with transparent nail pol-
ish. Images were captured by confocal laser scanning mi-
croscopy (ZEISS LSM510 META).
Viral growth in cells transfected with anti-vsRNA1 sponge
RNA and vsRNA1
RD cells were infected with EV71/4643/MP4 at an MOI
of 10. The virus was adsorbed for 1 h at 37◦C. After viral
adsorption, the infected cells in each well were transfected
with 160 pmol of synthetic mimic vsRNA1 (5′-GUAA
CUUAGAAGCUGUAAAUCAACGAUCA-3′) or scram-
bled vsRNA1 (5′-AAUGCUAUGAGACUAAUGAUAC
CAAGACU-3′) and 4 l of Lipofectamine 2000 (Invitro-
gen). For the anti-vsRNA1 sponge RNA experiments, the
infected cells were transfectedwith 1g of the anti-vsRNA1
sponge or scrambled RNA and 2 l of Lipofectamine 2000
(Invitrogen). For the LNA experiment, the infected cells
were transfected with 80 pmol/ml of LNA-vsRNA1 (5′ LN
A-TUGAUUUACAGCUUCU) or LNA-control (5′ LNA-
CAGUACUUUUGUGUAGUACAA) after virus adsorp-
tion. The viral titer was determined using plaque assays
with RD cells.
35S-methionine/cysteine labelling
We seeded 2.5 × 105 RD cells into each well of 12-
well plates and incubated them for 24 h. The cells were
then infected with EV71/4643/MP4 at an MOI of 10.
The virus was adsorbed for 1 h at 37◦C. After virus
adsorption, the infected cells in each well were trans-
fected with 160 pmol of synthetic mimic vsRNA1 (5′-
GUAACUUAGAAGCUGUAAAUCAACGAUCA-3′) or
scrambled vsRNA1 (5′- AAUGCUAUGAGACUAAU-
GAUACCAAGACU -3′) by 4 l of Lipofectamine 2000
(Invitrogen). For anti-vsRNA1 sponge experiments, the in-
fected cells were transfected with 1 g of sponge RNA
or control RNA. The medium was then replaced with
methionine/cysteine-free DMEM, and incubated again at
37◦C. At 4 h p.i., the medium was replaced with another
medium containing 35S-Met labelling (50 mCi/ml). After 1
h of labelling, the cell monolayers were washed with PBS
and lysed with a lysis buffer. Cell lysates were isolated by
centrifugation at 12,000 g for 10 min at 4◦C, and the super-
natants were collected for further analysis. Radiolabelled
proteins were resolved by SDS–PAGE (12% gels), trans-
ferred to a PVDF membrane, and detected by autoradio-
graphy.
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Preparation of SF268 cell extracts for in vitro translation as-
say
Toperform the in vitro IRES activity assay, SF268 cells were
washed in PBS and removed by scraping. The packed cells
were resuspended in a hypotonic buffer (10mMHEPES pH
7.9, 1.5 mM MgCl2, 10 mM KCl and 0.5 mM DTT) and
homogenized using a 25G needle. Homogenized cell frag-
ments were mixed with one volume of a working buffer (40
mM HEPES, 40% glycerol, 200 mM KCl, 0.4 mM EDTA
and 1 mM DTT at pH = 7.4) and vortexed for 30 s. After
centrifugation at 25,000 g, the extracted cell proteins in the
supernatant were harvested and stored at –80◦C.
In vitro translation assay
The study co-incubated 0.5 g of EV71 5′ UTR FLuc
reporter RNA and 60 pmol of vsRNA1 or scrambled
vsRNA1 or modified vsRNA1 containing vsRNA1163–165
[5′-(GUAACUUAGAAGCUGUAAAAGUACGAUCA)-
3′], vsRNA1174–176 [5′-(GUAACUUACUUGCUGUAA
AUCAACGAUCA)-3′] and vsRNA1163–165/174–176 [5′-
(GUAACUUACUUGCUGUAAAAGUACGAUCA)-3′]
with 50 g SF268 cell extracts and 4U RNaseOUT
recombinant ribonuclease inhibitor (Invitrogen) in a
volume of 20 l. The mixtures were incubated at 30◦C
for 5 min. After incubation, the reactions were used to
perform in vitro translation at a volume of 25 l. These
mixtures contained 0.5 g EV71 5′ UTR FLuc reporter
RNA, 60 pmol of mimic RNA1 or scrambled vsRNA1,
50 g of SF268 cell extract and 20% rabbit reticulocyte
lysate (RRL) (Promega). The in vitro IRES activity assay
followed the protocol of the Rabbit Reticulocyte Lysate
System (Promega). The mixtures were incubated at 30◦C
for 90 min, and firefly and Renilla luciferase activity was
measured using the Luciferase assay system (Promega).
Polysome profiling
7.2 × 106 SF268 cells were infected with EV71 at a MOI of
10. After 1 h adsorption, cells were transfected with the con-
trol (scrambled) RNA or vsRNA1mimic for 6 h. Cells were
treatedwith 0.1mg/ml cycloheximide for 5min at 37◦C, and
then washed twice with ice-cold PBS containing 0.1 mg/ml
cycloheximide. Cells were then lysed using 1 ml polysomal
extraction buffer (20 mM Tris-Cl, pH 7.5, 5 mM MgCl2,
100 mM KCl, 1% Triton-X-100 and 0.1 mg/ml cyclohex-
imide) on ice for 30 min. Cell debris was removed by cen-
trifugation at 15,000 g for 5 min, and the cell extracts were
layered onto 10 ml 7–47% sucrose gradients (comprising 20
mM Tris-Cl pH 7.5, 5 mMMgCl2 and 100 mMKCl). Sub-
sequently, the gradients were centrifuged at 35,000 rpm for
150 min in a Beckman SW41-Ti rotor at 4◦C. The gradi-
ents were fractionated with the Isco fractionator by pump-
ing a 60% sucrose solution into the bottom of the tube. The
fractions were then collected from the top of the tube and
the optical density was measured at 254 nm (OD254). The
ribosome subunits were detected in each fraction by West-
ern blotting using specific antibodies directed against the S6
(#2211; Cell Signaling) and P0 (NBP1–57528; Novus) ribo-
somal proteins.
Statistical analysis
Significant differences were determined by performing two-
tailed Student’s t-test using Prism 5 software (GraphPad).
RESULTS
EV71 infection generates virus-derived small RNAs
Previous studies have shown that the insertion of a het-
erologous miRNA-precursor stem-loop sequence element
into a cytoplasmic RNA virus can induce the production
of vsRNA in infected mammalian cells (11–13). Moreover,
a subset of positive-stranded cytoplasmic RNAviruses con-
tain a highly structured IRES region in their genomic RNA
(36). The 5′UTR of the EV71 genome (nt 1–745) contains
a highly structured IRES and a cloverleaf, which is asso-
ciated with viral replication and translation (19). To deter-
mine whether vsRNA was generated from the 5′UTR dur-
ing EV71 infection, we deep sequenced small RNAs un-
der 50 nt in EV71-infected SF268 cells. Only 0.05% of the
detected total RNA (17 922 of 33 539 716 reads) was de-
rived from viral RNA, which is consistent with findings by
Parameswaran et al. (14). Among these vsRNAs, most of
the reads (98%) were derived from viral positive-stranded
RNA. Small RNAs in infected cells containing sequences
that perfectly matched the 5′UTR of viral genomic RNA
were identified (Figure 1A). We named these vsRNAs vs-
RNA1, vsRNA2, vsRNA3 and vsRNA4. Three of the same
small RNAs, vsRNA1, vsRNA2 and vsRNA3, were also
detected in EV71-infected RD cells (Supplementary Figure
S1), suggesting that these small RNAs are generated by a
specific mechanism rather than by random degradation.
To confirm the existence of vsRNAs in EV71-infected
cells, we designed probes based on the most widespread vs-
RNA sequences in the deep-sequencing results (Figure 1A).
Northern blots showed that vsRNAs 1, 2, 3 and 4 were gen-
erated in infected SF268 cells (Figure 1B). These results also
suggested that only a small portion of the precursor was
processed into vsRNA, which was similar to previous find-
ings in another RNA virus (8). Among the four vsRNAs
detected in the 5′UTR of SF268 cells, the dominant vsRNA
(i.e., vsRNA1) showing the highest number of reads was se-
lected for further study. Based on the deep sequencing re-
sults (Figure 1A), themost widespread coverage of vsRNA1
was derived from nt 105–133 of the EV71 5′UTR, which is
located within the double-stranded region of the predicted
stem-loop II structure, illustrated by Context Fold software
(37) (Figure 1C). To confirm whether vsRNA1 was gener-
ated from nt 105–133 of the EV71 5′UTR, we generated
an EV71 replicon in which nt 105–133 of the EV71 5′UTR
were deleted (Rep-105–133). Only wild-type (WT) EV71
replicon-transfected cells generated vsRNA1 (Figure 1D,
lower panel). Taken together with the in vitro cleavage data
(see below; Figure 2E), this result confirmed that the vs-
RNA1 generation site is located in nt 105–133. A single cell
must have a minimum of 100 copies of miRNA to be capa-
ble of specific functions (13,38). To elucidate whether EV71
infection could generate a sufficient amount of vsRNA1, we
quantified the levels of vsRNA1 in 2.5 × 106 infected cells
by comparing them with known amounts of synthetic vs-
RNA1 (Figure 1E). Approximately 3.6× 105, 7.2× 105 and
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Figure 1. Identification of vsRNAs within the EV71 5′UTR. (A) Virus-derived small RNAs (vsRNAs) in SF268 cells infected with EV71 were sequenced
using Illumina technology. The position distributions and abundance (reads) of that sequenced vsRNAs that perfectlymatched the EV71 5′UTRare shown.
(B) vsRNA1–4 (black arrow) in mock- or EV71-infected SF268 cells were detected with 32P-labelled probes containing nucleotides against positions 105–
133, 178–198, 522–546 and 694–715 of the EV71 5′UTR. U6 snRNA was used as a loading control. (C) The secondary RNA structure of stem-loop II of
the EV71 5′UTR was predicted using Context Fold software (37) and was illustrated with jViz.RNA 2.0 software (http://jviz.cs.sfu.ca/). Circles indicate
the predicted vsRNA1 generation site, based on the deep sequencing result. (D) Precursor RNA (upper panel) and vsRNA1 (middle panel) from wild-type
EV71 replicon or the vsRNA1 deletion mutant (105–133) replicon EV71 in transfected SF268 cells were detected using 32P-labelled probes against nt
250–270 and nt 105–133 of the viral genome. U6 snRNA was used as a loading control (lower panel). (E) At 3, 6, 9 and 12 h p.i. with EV71, vsRNA1 in
human rhabdomyosarcoma (RD) and SF268 cells (from 2.5 × 106 cells per lane) was detected and compared to the indicated levels of synthetic vsRNA1
(mimic vsRNA1). RNA in mock-infected cells (m) served as a negative control. Viral protein 3C and actin were detected by western blotting.
1.2 × 106 copies of vsRNA1 were produced in a single in-
fected cell at 6, 9 and 12 h p.i. (1.5 pmol [6 h p.i.], 3 pmol [9
h p.i.] and 5 pmol [12 h p.i.] of vsRNA1 in 2.5 × 106 cells).
Argonaute2 (Ago2) associates with miRNA as functional
partner to induce targeted RNA degeneration or transla-
tional repression (39–41). To examine whether vsRNA1 as-
sociated with Ago2, we performed an immunoprecipitation
assay. An anti-Ago2 antibody enriched both vsRNA1 and
an endogenous miRNA (miR-21) from infected cells (Sup-
plementary Figure S2). In summary, we found that EV71
infection generated a substantial level of vsRNA1, which
associated with Ago2 in infected cells.
Dicer cleaves EV71 5′UTR and generates vsRNA1
The previous result demonstrated that EV71-infected cells
could generate a substantial level of vsRNA1 (Figure 1).
We were curious about how vsRNA1 is generated in in-
fected cells. The canonical mechanism of the production
of small RNAs or miRNAs in mammalian cells requires
both nuclear and cytoplasmic activities (1). However, EV71
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Figure 2. Dicer cleaves the EV71 5′UTR into vsRNA1. (A) vsRNA1 in SF268 cells transfected with the control plasmid (shControl) or a plasmid expressing
shRNA against Dicer (shDicer) was detected using the vsRNA1 probe. The levels of Dicer and viral 3C protein in these cells were detected by western
blotting. (B) In vitro EV71 5′UTR cleavage assay with recombinant Dicer. The 32P -labelled EV71 5′UTR and 3′UTR RNA was detected after being
incubated with reaction buffer only (-) or with various amounts (from 0.005 to 0.25 U) of recombinant Dicer for 1.5 h at 37◦C. (C) Dicer protein contains 2
RNAse III domains (RIIIDa and RIIIDb) and a dsRBD. N-terminal FLAG-fused Dicer protein (WT) and mutated Dicer proteins with 4 point mutations
(*) in the catalytic sites of RIIIDa / RIIIDb (MUT) and with a dsRBD deletion (dsRBD) were used for the in vitro cleavage of the EV71 5′UTR RNA.
The 32P-labelled EV71 5′UTR RNA was detected after being incubated with reaction buffer or with these FLAG-Dicer proteins at 37◦C for 1.5 h (upper
right panel). The FLAG-Dicer proteins in each reaction were detected using an antibody against the FLAG peptide (lower right panel). (D) A vsRNA1
probe was used to detect vsRNA1 generated by EV71-infected cells (Cell RNA) and by synthetic EV71 5′UTRRNA after Dicer treatment (Dicer-treated).
RNA isolated from mock-infected cells and from a synthetic 5′UTR without Dicer treatment (Un-treated) served as negative controls. (E) Detection of
vsRNA1 in wild-type (WT) or 105–133 mutant EV71 replicon RNA treated with recombinant Dicer. Full-length replicon RNA and vsRNA1 were
detected using a 32P-labelled probe against nt 250–270 and nt 105–133 of the viral genome.
is a cytoplasmic virus; it cannot access the nucleus for vs-
RNA generation. A non-canonical, Dicer-dependent but
DGCR8-independent pathway has been shown to gener-
ate functional small RNA from a cytoplasmic RNA virus
(12,13). The Dicer enzyme cleaves structured RNAs into
various small RNAs (7,42–43). Therefore, we hypothesised
that Dicer processes stem-loop II of the EV71 5′UTR (Fig-
ure 1C) into vsRNA1 in virus-infected cells. To investigate
whether Dicer is involved in the generation of vsRNA1,
we attempted to detect vsRNA1 in Dicer-depleted cells in-
fected with EV71. Unlike the measurable signal in con-
trol cells (Figure 2A, lane 1), vsRNA1 was undetectable in
the Dicer-depleted cells (lane 2). This result suggested that
Dicer is involved in vsRNA1 generation during EV71 in-
fection.Moreover, the same experiments demonstrated that
the generations of vsRNA2, vsRNA3 and vsRNA4 are also
Dicer-dependent (Supplementary Figure S3). Ago2 is in-
volved in non-canonical cytoplasmic small RNAprocessing
(44,45). To verify that Ago2 participates in vsRNA1 gen-
eration, we quantified vsRNA1 in Ago2-depleted cells in-
fected with EV71; Ago2 knockdown did not affect vsRNA1
generation (Supplementary Figure S4). An in vitro cleavage
assay was performed to determine whether Dicer cleaves
the EV71 5′UTR. An increase in the amount of recombi-
nant Dicer resulted in a reduction of the full-length 32P-
labelled EV71 5′UTR (Figure 2B, lanes 1–4) without affect-
ing EV71 3′UTR (lanes 5–8), indicating that Dicer specifi-
cally cleaves viral RNAs at this region. As Figure 2C shows,
Dicer contains 2 RNase III catalytic domains (RIIIDa
and RIIIDb) and a double-stranded RNA-binding domain
(dsRBD), which are essential for Dicer cleavage (31). We
further confirmed the potential Dicer cleavage on 5′UTR
using 2 Dicer mutants as controls: Dicer-MUT (mutations
in the catalytic sites of the two RNase III domains abro-
gate the RNase activity (46)) and Dicer-dsRBD (a dele-
tion mutant of dsRBD). Dicer-WT, Dicer-MUT andDicer-
dsRBD were fused to FLAG and transfected into SF268
cells. FLAG-immunoprecipitation (IP) was performed to
purify Dicer proteins, which were then quantified (Fig-
ure 2C, lower right panel). The WT and mutant forms of
Dicer were used for in vitro cleavage assays. Dicer-WT (Fig-
ure 2C, upper right panel, lane 2), but not Dicer-MUT
or Dicer-dsRBD (lanes 3 and 4), caused a reduction in
the level of EV71 5′UTR RNA, suggesting that Dicer may
cleave viral RNA through its RNase activity. Recombinant
Dicer was also noticed to cleave RNAs other than EV71
5′UTR in vitro, which may be a result of RNase activity.
To confirm that Dicer specifically generated vsRNA1 in in-
fected cells after cleaving the EV71 5′UTR RNA, we com-
pared the vsRNA1 produced in virus-infected cells to that
produced in the in vitro assays (5′UTR RNA + Dicer).
Both EV71 infection and the Dicer-treated 5′UTR RNA
generated vsRNA1 (Figure 2D). Because Dicer can cleave
double-stranded RNA into RNA duplexes, we also sought
to confirmwhether Dicer cleavage may produce small RNA
from 163–181 nt, the complement region of the vsRNA1-
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generation site in SLII (Figure 1C). The results indicated
that both EV71 infection and Dicer-treated 5′UTR RNA
can generate small RNA 163–181 (Supplementary Figure
S5).We previously demonstrated that vsRNA1was not gen-
erated in cells transfected with the EV71 105–133 repli-
con (Figure 1D). To further confirm that Dicer generated
vsRNA1 from the same region of viral RNA as in in-
fected cells, we treated the WT and mutant (Rep-105–
133) replicon RNA with Dicer and examined the genera-
tion of vsRNA1. vsRNA1 was detected in the Dicer-treated
WT replicon (Figure 2E, lower panel, lane 2) but not in the
Dicer-treated Rep-105–133 (lane 4). No nonspecific small
RNA fragments were detected by probing regions other
than vsRNA1 (Figure 2E, upper panel), suggesting that the
in vitro Dicer cleavage and the viral infection generated vs-
RNA1 from the same region of the viral RNA (Figures 1D
and 2E). Overall, these results suggest that Dicer cleaves the
EV71 5′UTR and generates vsRNA1 from nt 105–133 of
the EV71 5′UTR in infected cells.
The association of Dicer and EV71 5′UTR RNA
The binding of Dicer to double-stranded RNA is cru-
cial for the recognition and cleavage of Dicer’s substrate
(31,47–48). Because Dicer dsRBD is also essential for EV71
5′UTR cleavage (Figure 2C, upper right panel), we exam-
ined whether Dicer specifically associated with the EV71
5′UTR RNA. Dicer RNase III activity requires Mg2+, and
the RNase activity of Dicer was found to be inhibited by
EDTA in a Dicer-binding assay (46). Here, we used EDTA
in an RNA pull-down assay to examine whether endoge-
nous Dicer associates with the viral 5′UTR. A biotinylated
RNA containing the EV71 5′UTR was incubated with an
SF268 cell lysate, and streptavidin beads were used to pull
down biotinylated RNA and its associated proteins. Us-
ing western blotting, we detected Dicer in the RNA-protein
complex (Figure 3A, lane 5). Drosha, another RNase III
with a significant role in cellular miRNA biogenesis, was
not present in the complex (lower panel, lane 5). Dicer
was associated with the EV71 5′UTR not only in SF268
(human glioblastoma) cells but also in RD (human rhab-
domyosarcoma) and SK-N-MC (human neuroepithelioma)
cells (Figure 3B, lanes 3, 6 and 9). This association was con-
firmed by a competition assay with unlabelled EV71 5′UTR
RNA (Figure 3C, upper panel) or unstructured poly(A)
RNA (lower panel). Native gel electrophoresis confirmed
the interaction between Dicer and the 5′UTR. The 32P-
labelled 5′UTR (745 nt) formed a complex with recombi-
nant Dicer, and the migration of the RNA-protein complex
was retarded in the native gel (Figure 3D, lane 2). The re-
tardation decreased and the free RNA increased after cold
competitor RNA (EV71 5′UTR) was added (Figure 3D,
lanes 3–9). There was no effect on the 5′UTR-Dicer com-
plex when nonspecific poly(A) RNA was added to the reac-
tions (Figure 3E, lane 2 versus lanes 3–9). The RNA bind-
ing of Dicer was dose-dependent (Figure 3F). These results
indicated that Dicer associates with the EV71 5′UTR in
vitro. Next, we examined the location of Dicer in EV71-
infected cells. EV71 replicates in the cytoplasm, whereas the
localisation of several cellular proteins is altered in virus-
infected cells (26–27,29,49). A recent report also showed
that Drosha relocalised to the cytoplasm and contributed
to viral RNA processing in Sindbis virus-infected cells (13).
Therefore, we examined the locations of both Dicer and
Drosha in EV71-infected cells. The results showed that the
majority of Dicer was distributed in the cytoplasm (Fig-
ure 3G, upper panel), whereas Drosha was found mainly in
the nucleus (lower panel). These results further supported
the conclusion that Dicer cleaves the EV71 5′UTR to gen-
erate vsRNA1.
vsRNA1 downregulates virus infection and viral protein syn-
thesis
We had demonstrated that EV71-infected cells generated
a substantial amount of vsRNA1 through Dicer cleavage
(Figures 1 and 2). We next examined the effect of vsRNA1
on EV71 infection. To determine whether EV71 infection
generates functional vsRNA1, we blocked vsRNA1 in in-
fected cells using a strategy similar to the miRNA sponge
(50). As shown by Ebert et al. (50), this kind of sponge
RNA competes with the RNA that binds to small RNA,
ultimately blocking its function. We generated an anti-
vsRNA1 sponge RNA containing 10 repeats of sequences
that were the reverse complement of vsRNA1. We also
designed an RNA containing 10 repeats of scrambled se-
quence as a control. The anti-vsRNA1 and control sponge
RNA were transfected into EV71-infected cells. The viral
yield in the anti-vsRNA1 spongeRNA-transfected cells was
significantly higher than in the control RNA-transfected
cells (Figure 4A). To investigate whether vsRNA1 influ-
ence viral infection at viral replication stage in cytoplasm,
we co-transfected the anti-vsRNA1 sponge RNA or con-
trol RNA with an EV71 replicon encoding a firefly lu-
ciferase gene, which was used to quantify the viral protein
expression. The luciferase signal from the replicon in the
anti-vsRNA1-transfected cells was higher than in the con-
trol RNA-transfected cells at 9, 12 and 15 h after repli-
con transfection (Figure 4B), similar to the result in in-
fected cells (Figure 4A). We also monitored newly syn-
thesised proteins in anti-vsRNA1 sponge RNA-transfected
cells by performing a 35S-methionine/cysteine labelling as-
say. The level of the labelled viral proteins in the anti-
vsRNA1 sponge-transfected cells was higher than in the
control RNA-transfected cells (Figure 4C, lane 4 compared
with lane 3).Western blotting for a viral protein (3Cpro) also
confirmed the enhancement of viral protein expression by
the anti-vsRNA1 sponge. The anti-vsRNA1 sponge did not
affect host translation in mock-infected cells, which high-
lighted the specificity of the anti-vsRNA1 sponge for viral
sequences (Figure 4C, lane 2 compared with lane 1). These
results (Figure 4A–C) indicate that viral infection can gen-
erate functional vsRNA1, which downregulates viral yields
and viral protein synthesis.
To further examine the effect of vsRNA1 on EV71 in-
fection, we measured the viral titers in cells challenged
with EV71, followed by transfection with a mimic vs-
RNA1 (the mimic RNA used in Figure 1E) or scram-
bled RNA. To simulate the vsRNA1, which is only pro-
duced during viral infection, and to avoid possible side
effects resulting from long-term vsRNA1 expression, we
transfected vsRNA1 or scrambled RNA into the cells at
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Figure 3. The association between Dicer and the EV71 IRES. (A) In vitro Dicer and Drosha were coprecipitated with EV71 5′UTR. Proteins from SF268
cell lysates were incubated with biotin-UTP (biotin only), unlabelled (Non-bio), or biotin-labelled (Biotin) EV71 5′UTR RNA and streptavidin beads.
Proteins from lysates without incubation (No RNA) were pulled down by the same beads and served as a negative control. The Dicer and Drosha proteins
in the pull-down reactions or in 1/10 of the SF268 lysate before the pull-down (Input) were detected using western blotting. (B) The same in vitro Dicer and
Drosha pull-down assay as (A) was performed on lysates from RD, SK-N-MC and SF268 cells. (C) Competition assay for Dicer association with the EV71
5′UTR. Lane 1 contained the cell lysate (Input) only. The unlabelled EV71 5′UTR (Nonbio-EV71 5′UTR; zero (-) to 30 g) or poly(A) RNAwas added to
compete with 3 g of the biotinylated EV71 5′UTR probe interacting with Dicer in the SF268 cell lysate. Protein that was pulled down without adding any
RNAwas the negative control (No RNA). (D and E) The complex between recombinant Dicer and the EV71 5′UTRRNA. The 32P-labelled EV71 5′UTR
RNA was incubated with 0.4 U of recombinant Dicer (+Dicer) and varying amounts (40 to 400 ng) of unlabelled EV71 5′UTR RNA (+cold 5′UTR) (D)
or poly(A) RNA (E). The resulting complexes were analysed using native gel [non-denaturing 3% polyacrylamide TBE gels (29:1 acryamide:bisacryamide)]
ectrophoresis. EV71 5′UTR RNA that was not incubated with Dicer and cold 5′UTR (Free 32P 5′UTR) were used to determine the free RNA size. (F)
EV71 5′UTR RNA-protein complex formed with varying amounts of recombinant Dicer. Free 32P-labelled EV71 5′UTR RNA only (-) or 5′UTR RNA
incubated with varying amounts (0.08 to 0.8 U) of recombinant Dicer (+Dicer) was analysed using the same native gel electrophoresis. (G) The locations
of Dicer and Drosha in EV71-infected SF268 cells were detected using specific antibodies at 6 h p.i. The viral 2B and 3D proteins in SF268 cells were used
as markers of infection. The nuclei of the cells were stained with Hoechst dye.
1 h p.i. There were significantly lower viral yields in the
cells transfected with vsRNA1 than in those with scram-
bled RNA (Figure 4D). We also cotransfected the mimic
vsRNA1 or scrambled RNA with the EV71 replicon into
cells. The luciferase signal was lower from the replicon in
the vsRNA1-transfected cells than in the scrambled RNA-
transfected cells (Figure 4E). The newly synthesised pro-
teins in the vsRNA1-transfected cells were monitored us-
ing 35S-methionine/cysteine labelling. vsRNA1 inhibited
viral protein synthesis (Figure 4F, lanes 3 and 4) but not
host protein translation (mock, lanes 1–2). The effect of vs-
RNA1 was also confirmed by detecting 3C viral protein ac-
cumulation at 5 h p.i. using western blotting (Figure 5F,
lanes 3–4, lower panel). Taken together, these results sug-
gest that vsRNA1 plays a role in downregulating viral pro-
tein synthesis.
vsRNA1 inhibits viral IRES activity
We showed that vsRNA1 inhibits both cytoplasmic repli-
cation reactions and the virus productivity of infected cells.
Because the assays in Figure 4B, C, E and F demonstrated
that viral protein synthesis was downregulated by vsRNA1,
we hypothesised that vsRNA1 inhibits viral replication by
modulating viral translation. To determine whether vs-
RNA1 inhibits viral translation directly, we examined the
effects of vsRNA1 on EV71 IRES activity using a reporter
assay. We transfected SF268 cells with a single-stranded,
non-replicatable mRNA containing the EV71 IRES and
the coding sequence for firefly luciferase (FLuc, a reporter)
along with vsRNA1 or scrambled RNA (Scramb). The lu-
ciferase activity, which corresponded to EV71 IRES activ-
ity, was then measured. vsRNA1 inhibited up to 54% of
EV71 IRES activity in the transfected cells compared with
the scrambled RNA (Figure 5A, left panel). To determine
whether vsRNA1 reduces IRES activity by depleting the
RNA levels, we measured the RNA levels in transfected
cells using real-timeRT-PCRand northern blotting. Similar
RNA levels were observed in the vsRNA1-transfected cells
and the scramb-transfected cells (Figure 5A, right panel),
suggesting that vsRNA1 repressed viral translation without
degenerating the viral RNA. Certain viral RNAs can acti-
vate type I interferon (51,52) and cause global translational
repression in infected cells (53,54). To determine whether
vsRNA1 induces type I interferon, we examined interferon
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Figure 4. The effect of vsRNA1 on virus infection and viral protein synthesis. (A) Effect of anti-vsRNA1 sponge RNA on EV71 viral growth. EV71-
infected RD cells were transfected with the anti-vsRNA1 sponge or control RNA. After viral adsorption, viruses from the debris and the supernatant
were collected at 4, 8 and 12 h p.i. The viral yields were determined with plaque assays. Error bars represent standard deviations for duplicate assays
(*P < 0.05; **P < 0.01, Student’s t-test). (B) Effect of anti-vsRNA1 sponge RNA on EV71 replication. The luciferase activity in the EV71 replicon in
RD cells cotransfected with anti-vsRNA1 sponge or control RNA was monitored at 4, 6, 9, 12 and 15 h post-transfection. Error bars represent standard
deviations for three independent experiments (*P < 0.01; ***P < 0.001; Student’s t-test). (C) Effects of anti-vsRNA1 sponge on viral and host protein
synthesis. Mock- or EV71-infected cells were transfected with the anti-vsRNA1 sponge or control RNA. Protein synthesis in these cells was examined
using 35S-methionine/cysteine-labelling between 6 and 7 h p.i. The labelled viral proteins were identified according to their sizes. Viral protein 3C in the
cell lysates was detected by western blotting. (D) Effect of vsRNA1 on EV71 viral growth. EV71-infected RD cells were transfected with vsRNA1 mimic
or scrambled RNA. After viral adsorption, viruses from the debris and the supernatant were collected at 4, 8 and 12 h p.i. The viral yields were determined
using plaque assays. Error bars represent standard deviations for duplicate assays (***P <0.001), Student’s t-test). (E) Effect of the vsRNA1 mimic on
EV71 replication. Luciferase activity in the EV71 replicon in RD cells cotransfected with vsRNA1 mimic or scrambled RNA was monitored at 4, 6, 9, 12
and 15 h post-transfection. Error bars represent standard deviations for three independent experiments (*P < 0.05, ***P < 0.001, Student’s t-test). (F)
Effects of vsRNA1 on viral and host protein synthesis. Mock- or EV71-infected cells were transfected with vsRNA1 mimic or scrambled RNA (Scramb).
Protein synthesis in these cells was examined using 35S-methionine/cysteine-labelling between 4 and 5 h p.i. The labelled viral proteins were identified
according to their sizes. Viral protein 3C in the cell lysates was detected by western blotting.
expression in the scramb-, vsRNA1-, and Polyinosinic-
polycytidylic acid [poly (I:C)]-transfected cells. Transfecting
poly (I:C), but not vsRNA1 or control RNA, induced type
I interferon expression (Figure 5B). To determine whether
vsRNA1 inhibits host cap-dependent translation, we trans-
fected vsRNA1 and an in vitro-synthesised mRNA con-
taining a 5′ cap structure and the coding sequence for Re-
nilla luciferase into SF268 cells. vsRNA1 did not affect cap-
dependent translation (Figure 5C), which was similar to
the result that vsRNA1 did not affect cellular translation
(Figure 4F). vsRNA1 also inhibited the IRES activity of
poliovirus, another enterovirus (Figure 5D). Although we
demonstrated that vsRNA1 did not affect cellular transla-
tion (Figures 4F and 5C), we were still concerned that vs-
RNA1 transfection might be toxic to the cells. To rule out
possible bias produced by vsRNA1 transfection, we mea-
sured in vitro IRES activity to confirm the inhibitory effect
of vsRNA1 on viral translation. In this assay, vsRNA1 or
scrambled RNA was added to a mixture containing 20%
RRL, a HeLa cell translation extract, and EV71–5′UTR-
FLucmRNA. Similar to the results obtained for transfected
cells, vsRNA1 reduced EV71 IRES and polio-IRES activity
to 44%of the activity in control RNA-transfected cells (Fig-
ure 5E and F). The same as the transfected cells, vsRNA1
did not affect cap-dependent translation in this in vitro as-
say (Figure 5G). Therefore, vsRNA1 specifically inhibited
viral IRES activity in both live cells and in vitro reactions.
vsRNA1 inhibits viral translation by targeting the IRES
vsRNA1 inhibited viral IRES activity (Figure 5). To inves-
tigate whether vsRNA1 can inhibit IRES activity by tar-
geting a specific RNA region, we searched for potential vs-
RNA1 target sites using the entire IRES sequence.We iden-
tified a total of 10 potential target sites in the EV71 IRES.
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Figure 5. vsRNA1 inhibits viral IRES activity in vitro and in vivo. (A) Effect of vsRNA1 on EV71 IRES activity. SF268 cells were cotransfected with
either the vsRNA1 mimic or scrambled RNA (Scramb) combined with a reporter RNA containing the EV71 IRES and the firefly luciferase gene (EV71
IRES-FLuc). The EV71 IRES-driven luciferase expression (FLuc activity) is represented by bars. Error bars represent standard deviations (n = 3, *P <
0.05, Student’s t-test). The levels of the transfected reporter RNA (Luc-5′UTR) in the cells cotransfected with scrambled RNA (Scramb) or vsRNA1 were
assessed using quantitative real-time RT-PCR (qPCR) (upper right panel) and northern blotting (lower right panel). (B) IFN- mRNAs in Lipofectamine
2000-treated (Lipo) SF268 cells or cells transfected with scrambledRNA (Scramb); vsRNA1 and poly (I:C) were detected using qPCR. Error bars represent
standard deviations (n= 3). (C) The effect of the vsRNA1mimic on cap-dependent translation using a reporter RNA containing cap and Renilla luciferase
(Cap-RLuc). (D) RNAs containing the poliovirus IRES and the firefly luciferase gene (polio IRES-FLuc) were also examined (n= 3, *P< 0.05, Student’s
t-test). The effects of vsRNA1 on EV71 IRES activity (E), poliovirus IRES activity (F), and cap-dependent translation (G) were also examined in vitro.
Reporter RNAs incubated with the vsRNA1 mimic or scrambled RNA (Scramb) were examined in an in vitro translation assay using a mixture of SF268
cell lysate and rabbit reticulocyte lysate (RRL). The IRES- or cap-driven translation activity was determined according to the detected luciferase expression
(FLuc activity and RLuc activity). Error bars represent standard deviations for three independent experiments (*P < 0.05, Student’s t-test).
Such sites contained five contiguous nucleotides that were
the reverse complement of the vsRNA1 sequence. Because
vsRNA1 also inhibited polio IRES activity (Figure 5D and
F), we expected the sequences of the vsRNA1 target sites on
the polio IRES to be similar to those on the EV71 IRES.
We compared the sequences of EV71 and polio IRES to
narrow down the potential target sites. Four of the 10 po-
tential target sites, located at nt 162–166, 173–177, 366–
370 and 616–620 of the EV71 5′UTR, were similar to the
sequences of the polio IRES at the same locations (Fig-
ure 6A, grey boxes). We selected these four potential tar-
get sites for further study. To determine whether the four
target sites in the IRES are crucial for the inhibitory ef-
fect of vsRNA1, we mutated the three central nucleotides
of each potential target site in the EV71 5′UTR-FLuc RNA
(Figure 6A). All of the mutated EV71 5′UTR Fluc RNAs
were checked for their IRES activity using the wild-type
group as the reference category (Supplementary Figure S6).
An in vitro translation assay was performed to test the in-
hibitory effects of vsRNA1 on the activities of the mu-
tated reporter RNAs. Differently from the WT IRES that
was inhibited by vsRNA1, EV71 IRESs containing muta-
tions in nt 163–165 (mut 163–165), nt 174–176 (mut 174–
176) and double mutations (mut 163–165 and 174–176)
were found to be resistant to the inhibitory effect of vs-
RNA1 (Figure 6B). Mutations in nt 367–369 (mut 367–
369) and nt 617–619 (mut 617–619) of the IRES had no
effect on vsRNA1 resistance. To further confirm that mut
163–165, mut 174–176 and mut 163–165 + 174–176 be-
came resistant to vsRNA1 by losing the target sites in the
IRES, we generated vsRNA1s with sequence modifications
corresponding to the mutated IRES sites (vsRNA1163–165,
vsRNA1174–176 and vsRNA1163–165/174–176). Each modified
vsRNA1 substantially inhibited the corresponding mutant
IRES (80–90% inhibition) (Figure 6C). We also tested the
inhibitory effects of the modified vsRNA1s on WT IRES
activity. In vsRNA1163–165 and vsRNA1174–176, the ability
to inhibit the WT IRES was partially lost (20%–30% inhi-
bition) (Figure 6D). vsRNA1163–165/174–176 did not inhibit
the WT IRES, suggesting that nt 162–166 and nt 173–177
are the target sites for the inhibition of IRES activity by
vsRNA1. From these results, we concluded that vsRNA1
inhibits IRES activity by targeting specific sequences on
stem-loop II of the IRES (Figure 6E, upper panel). Notably,
more than 80% of the vsRNA1 deep sequencing reads con-
tained both of these active sequences (Supplementary Fig-
ure S7). To verify that the target sites identified in the in
vitro assay were valid in infected cells, we designed a tiny
LNA (anti-vsRNA1 LNA) to disrupt the association be-
tween the target sites and vsRNA1 (Figure 6E, lower panel).
Based on the results obtained by Obad et al., tiny LNA was
able to solely target the seed region of the miRNA, with-
out directly affecting the miRNA-targeted mRNA (55). We
also confirmed that our anti-vsRNA1 LNA did not target
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Figure 6. vsRNA1 target sites on IRES. (A) Predicted vsRNA1 target sites in the EV71 IRES (marked in grey) were selected based on conservation with
poliovirus (PV1). Based on the prediction, we generated mutations in nt 163–165, 174–176, 367–369 and 617–619 of the EV71 IRES in the reporter RNA.
(B) The inhibitory effects of vsRNA1 on WT and mutant IRES reporter RNAs. Each reporter RNA (including WT, mut 163–165, mut 174–176, mut
163–165, 174–175, mut 367–369 and mut 617–619) was treated with vsRNA1 or scrambled (control) RNA in an in vitro translation assay. The luciferase
activity in the vsRNA1 treatment assay was compared to the activity in the scrambled RNA treatment assay, and the percentage of IRES activity under
vsRNA1 treatment was calculated separately. Error bars represent standard deviations for three independent experiments (*P < 0.05, **P < 0.01, ***P
< 0.001, Student’s t-test). (C) Mutant IRES reporter RNAs were treated with the scrambled or vsRNA1 (or modified vsRNA1) that corresponded to
each target site mutant (vsRNA1163–165 to mut 163–165 IRES, vsRNA1 174–176 to mut 174–176 RNA and vsRNA1 163–165/174–176 to mut 163–165 +
174–176) in the in vitro translation assays. (D) WT IRES reporter RNA was treated with scrambled RNA or vsRNA1 (or modified vsRNA1) in an in vitro
translation assay. Error bars represent standard deviations for three independent experiments. (E) LNA against vsRNA1 was generated complementary
to the active sites (underlined) on vsRNA1 that target stem-loop II (SLII) of the EV71 5′UTR (the boxes indicate the vsRNA1 target sites). Effect of
anti-vsRNA1 LNA on EV71 viral growth. (F) EV71-infected RD and SF268 cells (MOI of 5) were transfected with LNA-vsRNA1 or LNA-control. After
viral adsorption, viruses from the debris and the supernatant were collected at the indicated times p.i. The viral yields were determined using plaque assays.
Error bars represent standard deviations for duplicated assays.
the EV71 IRES directly in an IRES activity assay (Supple-
mentary Figure S8). We transfected the anti-vsRNA1 LNA
or scrambled LNA into EV71-infected cells. The results
demonstrated that the anti-vsRNA1 LNA enhanced viral
infection in bothRDand SF268 cells (Figure 6F), providing
further confirmation of the vsRNA1 target sites identified
on the EV71 IRES in vivo.
DISCUSSION
This study showed that EV71 uses Dicer to generate small
RNAs inmammalian cells. One of these vsRNAs, vsRNA1,
downregulated IRES activity by targeting viral RNA (sum-
marised in Figure 7). It has been debated whether a cyto-
plasmic RNA virus in mammals can generate functional
small RNAs (38); however, our results show that this type
of virus can generate substantial amounts of vsRNA that
exhibits notable functions.
Because positive-stranded RNA viruses use the same
RNA as a template for both translation and replication,
strategies that control the switch between viral translation
and genome replication are crucial (24,25). For example,
poliovirus uses a host protein, Poly(rC)-binding protein 2
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Figure 7. Proposed model for the generation and function of vsRNA1.
During EV71 infection, a small proportion of viral RNA is processed by
Dicer, and vsRNA1 is generated from the IRES (purple). vsRNA1 targets
stem-loop II of the viral IRES (marked in green) and downregulates the
translation of viral proteins.
(PCBP2), to regulate both viral translation and replica-
tion (56–61). Viral proteases cleave host proteins, which
can enhance viral translation (62–64). This study revealed
a potential novel mechanism by which positive-sense RNA
viruses control their translation: generating vsRNAs and
self-regulating IRES activity. However, we cannot rule out
the possibility that the host may utilize such vsRNAs as a
defence mechanism against EV71 infections. Therefore, the
role of vsRNAs in virus infection deserves further scrutiny.
Recently, non-canonical cytoplasmic mechanisms have
been reported to contribute to small RNA biogenesis (11–
12,65). Dicer might be involved in these processes (14),
which correlates with our findings that Dicer is associated
with the generation of vsRNAs (Figures 2 and 3). The sub-
strate of Dicer is generally a stem-loop structure with both
5′ and 3′ ends (66). However, the EV71 5′UTR does not
contain such a structure, which is instead characterised by
long flanking regions at both ends of the stem-loop. Because
non-canonical Dicer substrates have been previously iden-
tified (67–69), the mechanisms by which this enzyme can
cleave the EV71 5′UTRRNA into vsRNA1 seem worthy of
investigation. We detected vsRNA1 as an RNA fragment
of 29 nt (Figure 1E), which is longer than the small RNA
generated by canonical Dicer processing (22 nt). However,
the bulged nucleotides on the stem-loops of pre-mRNAs
can increase the length of miRNA that Dicer is able to pro-
cess (70,71). The vsRNA1 generation site contains a bulged
structure (Figure 1C), whichmight explain howDicer cleav-
age generates a long small RNA.
Parameswaran et al. detected low-abundance vsRNA
reads in infected cells using deep sequencing (14). Coinci-
dently, we also detected limited numbers of vsRNA1 reads
in infected cells using deep sequencing (Figure 1A). To our
surprise, a northern blot, which was performed to con-
firm the absolute level of vsRNA1, showed that at least
105 vsRNA1 copies were generated from a single infected
cell (Figure 1E). Such inconsistent results between deep se-
quencing and other RNA detection methods have also been
found in previous studies (72,73). Factors such as differ-
ent PCR protocols, ligation steps in deep sequencing, or the
modification of the small RNA terminusmay bias the quan-
tification of small RNAs (73). We assume that these types
of bias caused our deep sequencing results to include under-
estimated levels of vsRNA. We cannot exclude the possibil-
ity that vsRNAs can undergo further unidentified modifi-
cations that should be the subject of future research. How-
ever, we demonstrated that infected cells could generate vs-
RNA1 in amounts sufficient for activity (Figure 4), which
seems to suggest that infected cells contain a substantial
level of vsRNA1. Besides vsRNA1, we also detected high
amounts of vsRNAs derived from regions other than the
5′UTR of the viral genomic RNA (Supplementary Figure
S9). Despite being outside the scope of the current report,
the potential role played by these vsRNAs in virus infection
is worthy of further scrutiny.
The function of small RNAs invariably requires the inter-
action with cellular proteins, including Argonaute 2 (Ago2)
(39–41). The question as to whether any cellular protein
is specifically required for vsRNA1 function is important
for characterizing the biological role of this molecule. Al-
though our data indicated that vsRNA1 can be associated
with Ago2 (Supplementary Figure S2), the experiments
conducted afterAgo2 depletion did not support the hypoth-
esis that this molecule is involved in either vsRNA1 biogen-
esis (Supplementary Figure S4) or in the inhibitory effect
on IRES activity (Supplementary Figure S10). Therefore,
the potential role of both vRNA1-associated Ago2 and/or
other vsRNA1-associated proteins warrants further inves-
tigation.
Besides the identification of vsRNA1-associated pro-
teins, it seems relevant to investigate whether vsRNA1 may
affect the binding of ITAFs to the EV71 IRES, especially at
the regions targeted by vsRNA1 (stem-loop II of the IRES).
Among the ITAFs that can bind to the SLII of EV71 IRES
(KSRP, hnRNPA1, PTB) (26–27,74), our preliminary re-
sults indicated that vsRNA1 can both enhance KSRP bind-
ing to the IRES (Supplementary Figure S11) and increase
the amount of KSRP sedimented in the fractions contain-
ing 40S and 60S ribosomal subunits, as compared with a
scrambled RNA sequence in a ribosome assembly experi-
ment (Supplementary Figure S12). KSRP has been shown
to act as a negative regulator of EV71 IRES activity (26,75).
The current observations suggest that vsRNA1 may inhibit
IRES activity by recruiting a negative regulator to the trans-
lational complex. The exact roles played by KSRP in vs-
RNA1 function and the detailed mechanisms of KSRP re-
cruitment elicited by vsRNA1 deserve further scrutiny.
Small RNAs are likely to play a role in determining
the tissue tropism of a given virus. For example, a host
miRNA122 targets the 5′ noncoding region of the hepati-
tis C virus (HCV) and enhances viral replication in hepa-
tocytes (76,77). Our deep-sequencing results demonstrated
significant differences (both in terms of levels and species)
in vsRNAs expression between RD (rhabdomysosarcoma)
Nucleic Acids Research, 2014, Vol. 42, No. 20 12803
and SF268 (glioblastoma) cells (Supplementary Figure S1),
suggesting a potential mechanism for viral tissue tropism.
Because blocking host miRNA122 using LNA represents
a novel treatment strategy for HCV infection (78,79), our
results may help developing novel potential antiviral strate-
gies in the prevention of EV71-associated neuropathogene-
sis.
In summary, our study demonstrates the ability of a cyto-
plasmic RNA virus to generate functional vsRNA in mam-
malian cells. In addition, we demonstrate a novel mecha-
nism for the self-regulation of positive-stranded RNA vi-
ral translation, which includes the generation of a vsRNA
that targets the IRES. Importantly, our data disclose a pre-
viously unknown role of vsRNA.
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